Beigene presented results from three pivotal trials at the 26th EHA2021 Virtual Congress for the effectiveness of their checkpoint inhibitor tislelizumab in relapsed or refractory lymphoma.

According to the CDC, the Delta variant now accounts for more than 6% of infections in the U.S. and may be responsible for 18% of cases in some Western states.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Health-related careers such as neuroscience jobs have been growing in the past decade, given how the development and advancement in technology and science have been significant during these years.

Metformin is a widely prescribed blood sugar-lowering drug. It is often used as an early therapy (in combination with diet and lifestyle changes) for type 2 diabetes, which afflicts more than 34 million Americans.

Metformin works by lowering glucose production in the liver, reducing blood sugar levels that, in turn, improve the body's response to insulin.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies' COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic.

David S. Knopman and Joel S. Perlmutter both resigned from the committee after the approval of the drug aducanumab.

Two of the company’s largest shareholders call for the ouster of a company director at Regeneron as top executives are under fire for their enormous compensation packages.

June appears to be a busy month for Series A financing rounds, with Kurome, Onchilles Pharma, and Hawthorne Effect closing in on millions of dollars worth of startup investments.

Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.

The new study findings may pave the way for Bristol Myers Squibb to receive additional approval for Breyanzi in a vulnerable patient population.

An immunocompromised patient in South Africa became a veritable COVID-19 variant laboratory as the virus mutated more than 30 times in 216 days of her infection, according to recent, not-yet-peer-reviewed research paper published in medRxiv.

​Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.

The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.

This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

John Edwards, newly-appointed CEO of Verseau Therapeutics, is continually searching for something special.

With an oral presentation and a poster at the ASCO Annual Meeting this year, Seres Therapeutics sought to bolster the case for two of its microbiome therapeutics programs.

If you’re considering preparing for your next interview, know that you need to learn the art of drafting a perfect cover letter to show that you’re a great match for the position.

What are the benefits of becoming a remote worker? Let’s explore together.